PBYI News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$507.4M

Volume

343.92K

Next Earnings

November 5th

Mkt Cap

$543.0M

Volume

343.92K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthFour pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027.Zacks Investment Research · Oct 16, 2026

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?Axsome Therapeutics reported Q2 2026 earnings that met EPS estimates but missed revenue expectations at $218.4M vs. $225M consensus. While lead drug Auvelity drove strong 51% YoY sales growth to $180.3M and Sunosi performed well, newest drug Symbravo significantly underperformed at $2.3M against $7.2M estimates. Post-earnings, analyst estimates have trended downward, and the stock has underperformed the S&P 500 by 3.7% over the past month.Zacks Investment Research · Sep 9, 2026

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer PatientsEr-Kim, an international pharmaceutical company, has signed an agreement with Puma Biotechnology to commercialize NERLYNX, a targeted therapy for early-stage HER2-positive breast cancer, in select countries in Eastern Europe and Central Asia.GlobeNewswire Inc. · Apr 30, 2025

Puma Biotechnology executive sells over $9,600 in stock - Investing.comPuma Biotechnology's Chief Commercial Officer, Jeffrey Jerome Ludwig, sold 2,598 shares of the company's common stock for over $9,600. The sale was part of a pre-arranged trading plan, and Ludwig's direct ownership in the company now stands at 118,388 shares.Investing.com · Jul 18, 2024

Puma biotech exec sells shares worth over $19,000 By Investing.com - Investing.com AustraliaPuma Biotechnology's Chief Commercial Officer Jeffrey Jerome Ludwig sold 6,051 shares worth over $19,000. The sale was executed under a pre-arranged trading plan. The company has reported a decrease in total and product revenue for Q1 2024, but is actively pursuing clinical trials and refining its distribution model.Investing.com · Jul 3, 2024

Puma Biotechnology executive sells over $14,000 in company stock By Investing.com - Investing.com AustraliaPuma Biotechnology's Senior Vice President of Regulatory Affairs, Douglas M. Hunt, sold over $14,000 worth of company stock. The sale may attract attention from investors as it comes amid recent developments, including a decline in revenue but a strong gross profit margin.Investing.com · Jul 3, 2024

Puma Biotechnology CFO sells shares worth over $17,000 By Investing.com - Investing.com AustraliaPuma Biotechnology's CFO, Maximo F. Nougues, has sold shares worth over $17,000. The transaction was executed under a 10b5-1(c) trading plan, which allows insiders to sell shares on a predetermined schedule. The company has also been selected for inclusion in the Russell 3000 Index, which is expected to increase liquidity and exposure to institutional investors.Investing.com · Jul 3, 2024

Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology StockRatings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. This current average has not changed from the previous average price target. Interpreting Analyst Ratings: A Closer Look The standing of Puma Biotechnology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00 Edward White HC Wainwright & Co. Maintains Buy $7.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.comBenzinga · Jun 4, 2024

Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's WhySales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.Zacks Investment Research · May 24, 2024

Implied Volatility Surging for Puma Biotechnology (PBYI) Stock OptionsInvestors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.Zacks Investment Research · May 20, 2024

PBYIPUMA BIOTECHNOLOGY INC

PBYI

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any PBYI yet.

Related Tickers

ADMA—

CTMX—

TRDA—

Earnings

Mkt Cap

$507.4M

Volume

343.92K

Next Earnings

November 5th